Vivos Therapeutics Agrees to Debt-to-Equity Exchange Amid Nasdaq Compliance Concerns

Vivos Therapeutics, Inc. has announced a binding agreement to convert up to $4.5 million of its secured note into preferred and common stock. This exchange is contingent on the company raising specific equity amounts by mid-June 2026. Concurrently, Vivos Therapeutics is also addressing ongoing Nasdaq compliance issues.